Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?

Archives of pathology & laboratory medicine - 1 Apr 2016

Borczuk Alain C, Allen Timothy Craig

Abstract excerpt

The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand-1 (PD-L1). The intense interest in drug development in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Immunohistochemistry

Share to Precision Medicine

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 26756646
DOI: 10.5858/arpa.2015-0509-SA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?PMID 26756646Read ↗

Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.Semantic proximity Read ↗

Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.Semantic proximity Read ↗

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.Semantic proximity Read ↗

Precision medicine in non-small cell lung cancer: Current applications and future directions.Semantic proximity Read ↗

[Molecular pathology of lung cancer in routine diagnostic practice: 2017 update].Semantic proximity Read ↗

Newly Diagnosed Lung Cancer: Which Molecular Tests Are Needed for Optimal Treatment Decision Making?Semantic proximity Read ↗

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity Read ↗

Pathways to Precision: Guideline for Programmed Death Ligand-1 and Tumor Mutation Burden Testing to Support the Selection of Immune Checkpoint Therapies in Lung Cancer.Semantic proximity Read ↗

Current status of molecular diagnostics for lung cancerSemantic proximity Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

PD-L1 as a biomarker in NSCLC: challenges and future directionsSemantic proximity Read ↗

Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.